Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma
article
Oncolytic adenoviruses exhibiting tumor-selective replication are promising anticancer agents. Insertion and expression of a transgene encoding tissue inhibitor of metalloproteinase-3 (TIMP-3), which has been reported to inhibit angiogenesis and tumor cell infiltration and induce apoptosis, may improve the antitumor activity of these agents. To assess the effects of TIMP-3 gene transfer to glioma cells, a replication-defective adenovirus encoding TIMP-3 (Ad.TIMP-3) was employed. Ad.TIMP-3 infection of a panel of glioma cell cultures decreased the proliferative capacity of these cells and induced morphologic changes characteristic for apoptosis. Next, a conditionally replicating adenovirus encoding TIMP-3 was constructed by inserting the TIMP-3 expression cassette into the E3 region of the adenoviral backbone containing a 24-bp deletion in E1A. This novel oncolytic adenovirus, AdΔ24TIMP-3, showed enhanced oncolytic activity on a panel of primary cell cultures and two glioma cell lines compared with the control oncolytic virus AdΔ24Luc. In vivo inhibition of matrix metalloproteinase (MMP) activity by AdΔ24TIMP-3 was shown in s.c. glioma xenografts. The functional activity of TIMP-3 was imaged noninvasively using a near-IR fluorescent MMP-2-activated probe. Tumoral MMP-2 activity was significantly reduced by 58% in the AdΔ24TIMP-3-treated tumors 24 hours after infection. A study into the therapeutic effects of combined oncolytic and antiproteolytic therapy was done in both a s.c. and an intracranial model for malignant glioma. Treatment of s.c. (U-87MG) or intracranial (U-87δEGFR) tumors with AdΔ24TIMP-3 and AdΔ24Luc both significantly inhibited tumor growth and prolonged survival compared with PBS-treated controls. However, expression of TIMP-3 in the context of AdΔ24 did not significantly affect the antitumor efficacy of this oncolytic agent. ©2005 American Association for Cancer Research. Chemicals / CAS: tissue inhibitor of metalloproteinase 3, 145809-21-8, 164781-40-2; Matrix Metalloproteinase 2, EC 3.4.24.24; Tissue Inhibitor of Metalloproteinase-3
Topics
Biomedical Researchoncolytic adenovirusoncolytic virustissue inhibitor of metalloproteinase 3Adenovirusanimal experimentanimal modelanimal tissueantineoplastic activityarticlecancer cell culturecancer modelcancer survivalcell proliferationcell strain HEK293controlled studyculture mediumdrug efficacyenzyme activityenzyme inhibitionfemalegene deletiongene expressiongene insertiongene transferglioblastomaglioma cellhumanhuman cellmousenonhumanpriority journalprotein expressionsurvival timetransgenetumor xenograftAdenoviridaeAnimalsCell Growth ProcessesCell Line, TumorGene Transfer TechniquesGliomaHumansMatrix Metalloproteinase 2MiceMice, NudeTissue Inhibitor of Metalloproteinase-3Virus ReplicationXenograft Model Antitumor Assays
TNO Identifier
238761
ISSN
00085472
Source
Cancer Research, 65(20), pp. 9398-9405.
Pages
9398-9405
Files
To receive the publication files, please send an e-mail request to TNO Repository.